Literature DB >> 21967367

What is the value of hypothermia in acute neurologic diseases and status epilepticus?

Andrea O Rossetti1.   

Abstract

Patients with status epilepticus that proves refractory to anesthetic agents represent a daunting challenge for treating clinicians. Animal data support the neuroprotective action of brain hypothermia, and its efficacy in status epilepticus models. This approach, targeting a core temperature of about 33°C for at least 24 hours together with pharmacological sedation, has been described in adults and children. However, although relatively safe if concomitant barbiturates are avoided, it seems that mild hypothermia rarely allows a sustained control of ongoing status epilepticus, since seizures tend to recur in normothermia. Conversely, mild hypothermia has a high-evidence level and is increasingly used in postanoxic encephalopathy, both in newborns and adults. Due to the paucity of available clinical data, prospective studies are needed to assess the value of hypothermia in status epilepticus. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Year:  2011        PMID: 21967367     DOI: 10.1111/j.1528-1167.2011.03241.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  10 in total

Review 1.  Status epilepticus: an update.

Authors:  Panayiotis N Varelas; Marianna V Spanaki; Marek A Mirski
Journal:  Curr Neurol Neurosci Rep       Date:  2013-07       Impact factor: 5.081

Review 2.  Neonatal seizures: controversies and challenges in translating new therapies from the lab to the isolette.

Authors:  Kevin E Chapman; Yogendra H Raol; Amy Brooks-Kayal
Journal:  Eur J Neurosci       Date:  2012-06       Impact factor: 3.386

3.  Selective head cooling during neonatal seizures prevents postictal cerebral vascular dysfunction without reducing epileptiform activity.

Authors:  Mimily Harsono; Massroor Pourcyrous; Elliott J Jolly; Amy de Jongh Curry; Alexander L Fedinec; Jianxiong Liu; Shyamali Basuroy; Daming Zhuang; Charles W Leffler; Helena Parfenova
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-09-02       Impact factor: 4.733

4.  Guidelines for the evaluation and management of status epilepticus.

Authors:  Gretchen M Brophy; Rodney Bell; Jan Claassen; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Suzette M Laroche; James J Riviello; Lori Shutter; Michael R Sperling; David M Treiman; Paul M Vespa
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

5.  Treatment of nonconvulsive status epilepticus.

Authors:  Trudy Pang; Frank W Drislane
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

Review 6.  Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Authors:  Elizabeth L Alford; James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

Review 7.  Electroencephalography in survivors of cardiac arrest: comparing pre- and post-therapeutic hypothermia eras.

Authors:  Amy Z Crepeau; Jeffrey W Britton; Jennifer E Fugate; Alejandro A Rabinstein; Eelco F Wijdicks
Journal:  Neurocrit Care       Date:  2015-02       Impact factor: 3.210

8.  Management of super-refractory status epilepticus with isoflurane and hypothermia.

Authors:  Agzam Zhumadilov; Charles P Gilman; Dmitriy Viderman
Journal:  Front Neurol       Date:  2015-01-28       Impact factor: 4.003

Review 9.  Neuroprotective effect of therapeutic hypothermia versus standard care alone after convulsive status epilepticus: protocol of the multicentre randomised controlled trial HYBERNATUS.

Authors:  Stephane Legriel; Fernando Pico; Yves-Roger Tran-Dinh; Virginie Lemiale; Jean-Pierre Bedos; Matthieu Resche-Rigon; Alain Cariou
Journal:  Ann Intensive Care       Date:  2016-06-21       Impact factor: 6.925

10.  Treatment of Super-Refractory Status Epilepticus: A Review.

Authors:  Juan G Ochoa; Michelle Dougherty; Alex Papanastassiou; Barry Gidal; Ismail Mohamed; David G Vossler
Journal:  Epilepsy Curr       Date:  2021-03-10       Impact factor: 7.500

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.